Revolution Medicines, Inc.
RVMD
Rang in Aktien
#644
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktienkurs
$176.71
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$37.88B
Veränderung (1 Tag)
-6.63%
Veränderung (1 Jahr)
226.64%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategorie
Healthcare
Operative Marge für Revolution Medicines, Inc. (RVMD)
Operative Marge zum October 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Revolution Medicines, Inc. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2023 lag die operative Marge bei -4,207.12%.
Historie der operativen Marge von Revolution Medicines, Inc. von 2017 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -4,207.12% | 476.31% |
| 2022 | -730.01% | 14.12% |
| 2021 | -639.70% | 148.39% |
| 2020 | -257.54% | 138.13% |
| 2019 | -108.15% | -45.93% |
| 2018 | -200.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.